CDC exercises options under Emergent smallpox vaccine therapeutic contract
VIGIV is a U.S. Food and Drug Administration-licensed therapeutic used to treat complications due to smallpox vaccinations. Emergent will supply VIGIV to the U.S. Strategic National Stockpile as part of a three-year, $18.9 million contract. The contract provides for the work needed to maintain FDA licensure of VIGIV and collect plasma for manufacturing in the future.
A recent contract modification by the CDC will increase the total contract value to $36.6 million.
"Emergent's ongoing integration of the Cangene operations has ensured continuity in the fulfillment of our procurement and development contracts with the U.S. government," Adam Havey, the executive vice president and president of Emergent's biodefense division, said. "With respect to VIGIV, which remains a critical component of the government's biodefense program, we are pleased that CDC has exercised these contract options and look forward to implementing the required activities that we anticipate will enable future manufacturing of VIGIV."
The CDC originally awarded the contract to Cangene Corporation, a company Emergent acquired in February. VIGIV was first delivered into the Strategic National Stockpile in 2002 and was licensed in the U.S. in 2005.
Emergent BioSolutions provides specialized products to governments and healthcare providers to address emergent health threats and medical needs.